24 October 2019 - Experts are raising the need to establish tools to calculate the value of new anticancer medicines due to the rising costs of national health insurance. 

However, industry officials express concerns that such devices could be used for “post-assessment,” which could remove existing drugs.

Korean Cancer Study Group held a public hearing titled “Analysis on Value Assessment Tools for Anticancer Drugs Overseas and Application in Korea,” at the Catholic University of Korea on Tuesday. Participants raised the necessity of developing anticancer drug evaluation tools, reviewed the progress of the discussion, and debated in which direction the next move should be.

Read Korean Biomedical Review article